Brief: Pacira Biosciences Announces Settlement Of U.S. Patent Litigation For Exparel
07/04/2025 21:43
April 7 (Reuters) - Pacira Biosciences Inc PCRX.O: PACIRA BIOSCIENCES ANNOUNCES SETTLEMENT OF U.S. PATENT LITIGATION FOR EXPAREL PACIRA BIOSCIENCES INC - FRESENIUS KABI LICENSED TO SELL GENERIC BUPIVACAINE IN U.S. FROM 2030 PACIRA BIOSCIENCES INC - FRESENIUS TO SELL GENERIC BUPIVACAINE WITHOUT LIMITATIONS FROM 2039 Source text: ID:nGNX71xX5B Further company coverage: PCRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pacira Biosciences
See all newsBrief: Pacira Biosciences Inc - Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "For" All Of Pacira's Director Nominees
Brief: Pacira Biosciences Urges Stockholders To Vote "For" Election Of Pacira's Nominees On Blue Proxy Card
Brief: Doma Perpetual Urges Pacira Biosciences Shareholders To Judge Sale Price Adequacy
Brief: Doma Perpetual Capital Management Calls For Removal Of Pacira CEO And Strategic Sale
Brief: Pacira Biosciences Sends Letter To Stockholders Reiterating Superior Qualifications Of Its Board Nominees